Biolife Solutions: (OTC: BLFS)
$0.36
-0.02 (-5.26%)
Volume 8,000
Jun 19 12:22 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.36 - 0.36 |
| 52wk Low - High | 0.07 - 0.47 |
| Previous Close | 0.38 |
| Avg. Volume | 5,355 |
| Industry | MED PRODUCTS |
| Market Cap | 26.61 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | -0.66 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.02 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
184 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.02 |
| Current Quarter Estimate | -0.01 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -0.03 |
| Expected Earnings Growth | NA |
Company Description
BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.01 | -0.01 | -0.02 | -0.02 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | -0.01 | -0.01 | -0.02 | -0.02 |
| High Estimate | -0.01 | -0.01 | -0.02 | NA |
| Year Ago EPS | -0.01 | -0.01 | -0.02 | -0.02 |
| EPS Growth | 0.00% | 0.00% | 0.00% | 0.00% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
| HAEMONETICS CP | HAE | 42.71 | |
|
| ATRICURE INC | ATRC | 9.12 | |
|
| BAXANO SURGICAL | BAXS | 2.28 | |
|
| CARDICA INC | CRDC | 1.19 | |
|
| ESSILOR INTL SA | ESLOY | 55.99 | |
|
| INVIVO THERAPT | NVIV | 3.89 | |
|
| PURE BIOSCIENCE | PURE | 0.41 | |
|
| SHANDONG WEIGAO | SHWGF | 1.29 | |
|
| ABAXIS INC | ABAX | 46.89 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
BLFS: Revenue Upside Surprise, Again...
Jan 07, 2013
BLFS: Revenue Upside Surprise, Again???
Jan 07, 2013
Q3 Results Beat Big. Revenue Guidance Increased
Nov 16, 2012
BLFS: Q2 Results. Guidance Affirmed
Aug 16, 2012
BLFS: Q2 Revenue Pre-Announcement
Jul 09, 2012
BLFS - Initiating Coverage
Jul 02, 2012
Report Not Available
Financials
| EPS TTM | -0.03 |
| Sales | 6 |
| Net Income | -1 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 3.81 |
News
BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress - Pr Newswire
May 23, 2013
BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013 - Pr Newswire
May 14, 2013
/C O R R E C T I O N -- BioLife Solutions, Inc./ - Pr Newswire
May 6, 2013
BioLife Solutions Announces Participation and Additional Product Citations at 19th ISCT Annual Meeting - Pr Newswire
May 6, 2013
BioLife Solutions Inc licenses CryoStor Cell Freeze Media to Janssen Research & Development LLC - M2
May 3, 2013
BioLife Solutions Announces License Agreement - Pr Newswire
May 2, 2013
BioLife Solutions Q4 net loss increases - Datamonitor
Apr 9, 2013
BioLife Solutions Appoints Rick Stewart To Board of Directors - Pr Newswire
Feb 4, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 0.90 |
| Industry Rank by ABR | 184 out of 265 |
| Rank in Industry | 9 out of 73 |
